Payment overview · 2025
General Payments
$373.41
23 reported records · 7 companies
Healthcare provider profile · identity verified
Zachary Robert Windrow, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HONDO, TX · NPI 1235161811
Verified facts
What the public records show
CMS Open Payments records show Zachary Robert Windrow, M.D. received $373.41 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 47.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $178.42 | 47.8% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $93.24 | 25.0% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.56 | 7.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.29 | 6.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.22 | 5.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.17 | 4.6% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.51 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $373.41 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $169.43 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $44.65 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.18 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $8.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 505 | 145 |
| Atorvastatin Calcium | Atorvastatin Calcium | 466 | 141 |
| Gabapentin | Gabapentin | 366 | 69 |
| Metformin Hcl | Metformin Hcl | 321 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 290 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 241 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 231 | 66 |
| Losartan Potassium | Losartan Potassium | 213 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 61 |
| Tramadol Hcl | Tramadol Hcl | 183 | 49 |
| Trazodone Hcl | Trazodone Hcl | 181 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 52 |
| Prednisone | Prednisone | 175 | 140 |
| Meloxicam | Meloxicam | 174 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 165 | 32 |
| Furosemide | Furosemide | 155 | 33 |
| Alprazolam | Alprazolam | 140 | 24 |
| Methylprednisolone | Methylprednisolone | 139 | 126 |
| Donepezil Hcl | Donepezil Hcl | 137 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 42 |
| Simvastatin | Simvastatin | 133 | 38 |
| Montelukast Sodium | Montelukast Sodium | 132 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 131 | 41 |
| Carvedilol | Carvedilol | 130 | 34 |
| Potassium Chloride | Potassium Chloride | 127 | 29 |
| Azithromycin | Azithromycin | 126 | 110 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 126 | 20 |
| Omeprazole | Omeprazole | 125 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 124 | 22 |
| Memantine Hcl | Memantine Hcl | 123 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 121 | 14 |
| Ozempic | Semaglutide | 114 | 24 |
| Sertraline Hcl | Sertraline Hcl | 109 | 30 |
| Pregabalin | Pregabalin | 107 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 13 |
| Allopurinol | Allopurinol | 102 | 30 |
| Buspirone Hcl | Buspirone Hcl | 101 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 72 | 57 |
| Risperidone | Risperidone | 71 | suppressed |
| Glimepiride | Glimepiride | 70 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 32 |
| Divalproex Sodium | Divalproex Sodium | 62 | suppressed |
| Lovastatin | Lovastatin | 61 | 14 |
| Celecoxib | Celecoxib | 59 | 19 |
| Ibuprofen | Ibuprofen | 59 | 16 |
| Myrbetriq | Mirabegron | 56 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 55 | suppressed |
| Eliquis | Apixaban | 54 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 11 |
| Lamotrigine | Lamotrigine | 52 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 49 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 13 |
| Glipizide | Glipizide | 47 | 11 |
| Januvia | Sitagliptin Phosphate | 47 | 11 |
| Propranolol Hcl | Propranolol Hcl | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 11 |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 41 | suppressed |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 13 |
| Nifedipine Er | Nifedipine | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Lorazepam | Lorazepam | 37 | 15 |
| Atenolol | Atenolol | 36 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Cephalexin | Cephalexin | 33 | 28 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | 11 |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 24 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 25 |
| Nystatin | Nystatin | 27 | 17 |
| Spironolactone | Spironolactone | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Constulose | Lactulose | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 18 |
| Naproxen | Naproxen | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | 12 |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Sucralfate | Sucralfate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Nizatidine | Nizatidine | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Rifampin | Rifampin | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $373.41 · 23 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CONTRAVE, Dexcom G6 Transmitter, FARXIGA, INSPIRE, QULIPTA, The Cologuard Plus Collection Kit, VRAYLAR, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error